http://purl.org/np/RAkoWjOLT2... RAkoWjOLT2

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-06T11:45:23.837Z

http://purl.org/np/RAkoWjOLT2... RAkoWjOLT2

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-06T11:45:23.837701

Elif Ozkan

2022-10-06T11:45:23.837Z

http://purl.org/np/RAkoWjOLT2... RAkoWjOLT2

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

Fosamprenavir calcium tablets are indicated in combination with other antiretroviral agents for the treatment of human immunodeficiency virus (HIV-1) infection. The protease inhibitor-experienced patient trial was not large enough to reach a definitive conclusion. Once-daily administration of fosampranavir. tabletsplus ritonavir is not recommended for adult. protease. inhibitor-expertienced patients or any pediatric patients. younger than 6 months.

Elif Ozkan

2022-10-06T11:45:23.837Z